Zimmer Biomet Holdings, Inc.

• ZBH Stock Price 24h change: +2.02%. From 86.55 USD to 88.30 USD. The stock rebounded as investors adjusted positions following a "cautious" 2026 guidance outlook provided during the J.P. Morgan Healthcare Conference earlier this month.
• From a technical perspective, ZBH presents a "bearish trend with short-term consolidation": the stock is trading below its 50-day ($88.15) and 200-day ($90.62) moving averages, with a 14-day RSI of 51.87 indicating a neutral momentum but overall technical ratings remain weak due to long-term price erosion.
• Zimmer Biomet management reiterated cautious expectations for 2026 on January 21, citing internal restructuring and "reset" scale, which has kept major institutional analysts like JPMorgan at a "Neutral" rating with a $100 price target.
• Rakuten Investment Management disclosed a new $37.31 million investment in ZBH on January 21, signaling some institutional confidence in the company's "wide moat" status despite recent volatility.
• On January 21, analysts from Bernstein maintained a "Market Perform" rating but slightly raised the price target to $99, noting improving macro clarity for U.S. healthcare and orthopedic stocks.
• The 2026 Vizient State of the Industry report released on January 22 highlights that the broader healthcare sector faces a "structural reset" due to financial risks and supply chain pressures, impacting medical device manufacturers' margins.
• Industry leaders in the MedTech sector called for a structured funding framework for R&D and innovation in upcoming 2026 budgets on January 22 to offset rising regulatory compliance costs in Europe and the UK.

• ZBH Stock Price 24h change: -0.58%. From 87.31 USD to 86.80 USD. The decline follows a broader multi-day bearish trend as investors weigh cautious 2026 outlooks despite recent Q3 earnings beats.
• From a technical perspective, the market presents a "Strong Bearish" signal: ZBH is trading below its 5, 20, 50, and 200-day simple moving averages. The RSI of 37.8 suggests it is approaching oversold territory, while the MACD remains negative, indicating continued downward momentum.
• Zimmer Biomet announced it will webcast its Fourth Quarter 2025 financial results on February 10, 2026, providing critical updates on its multi-year transformation strategy.
• Rakuten Investment Management disclosed a new $37.31 million stake in ZBH, signaling institutional interest despite the stock hitting near 52-week lows.
• Analysts at BTIG Research restated a "Buy" rating with a $112 price target, contrasting with Baird’s more cautious "Neutral" stance and lowered $100 price objective.
• North Carolina has become the second U.S. state to ban certain chemicals used in medical devices, forcing manufacturers to accelerate supply chain and material audits.
• The medical device industry is seeing a surge in M&A activity in early 2026, with major deals like Haemonetics’ €185 million acquisition of Vivasure signaling aggressive consolidation in specialized segments.